THURSDAY, Nov. 14, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and ...

The HC bench said Section 13 (1)(iii) of the Hindu Marriage Act does not make mere existence of a mental disorder of any ...

One of the most common archetypes in horror movies is the portrayal of a villain or killer as “crazy,” eliciting a consistent ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

People who land in the ER for psychedelic use are at significantly higher risk of schizophrenia, according to an eye-opening ...

Possibly the biggest news this week comes from the schizophrenia space, where AbbVie’s emraclidine failed two mid-stage ...

New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

Shares of AbbVie were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia ...